Clinical trials
Hypertension trials in Colombia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
36 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 4 |
| 2009 | 4 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Terminated | 5 |
| Recruiting | 4 |
| Unknown status | 4 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| Sanofi | 3 |
| Bayer | 2 |
| Boehringer Ingelheim | 2 |
| Closter Pharma | 2 |
| Universidad de Antioquia | 2 |
| Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 1 |
| Alnylam Pharmaceuticals | 1 |
| Arbor Pharmaceuticals, Inc. | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 36 |
| Cardiovascular Diseases | 5 |
| Renal Insufficiency, Chronic | 3 |
| Diabetes Mellitus | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Essential Hypertension | 2 |
| Acute Coronary Syndrome | 1 |
| Acute Kidney Injury | 1 |
| Atherosclerosis | 1 |
| Atrial Fibrillation | 1 |
Trials
Showing 1 to 25 of 36. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.